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Abstract
Background: The two myogenic regulatory factors Myf5 and MyoD are basic helix-loop-helix
muscle transcription factors undergoing differential cell cycle dependent proteolysis in proliferating
myoblasts. This regulated degradation results in the striking expression of these two factors at
distinct phases of the cell cycle, and suggests that their precise and alternated disappearance is an
important feature of myoblasts, maybe connected to the maintenance of the proliferative status
and/or commitment to the myogenic lineage of these cells. One way to understand the biological
function(s) of the cyclic expression of these proteins is to specifically alter their degradation, and
to analyze the effects of their stabilization on cells. To this aim, we undertook the biochemical
analysis of the mechanisms governing Myf5 mitotic degradation, using heterologous systems.
Results: We show here that mitotic degradation of Myf5 is conserved in non-myogenic cells, and
is thus strictly under the control of the cell cycle apparatus. Using Xenopus egg extracts as an in
vitro system to dissect the main steps of Myf5 mitotic proteolysis, we show that (1) Myf5 stability
is regulated by a complex interplay of phosphorylation/dephosphorylation, probably involving
various kinases and phosphatases, (2) Myf5 is ubiquitylated in mitotic extracts, and this is a
prerequisite to its degradation by the proteasome and (3) at least in the Xenopus system, the E3
responsible for its mitotic degradation is not the APC/C (the major E3 during mitosis).
Conclusion: Altogether, our data strongly suggest that the mitotic degradation of Myf5 by the
ubiquitin-proteasome system is precisely controlled by multiple phosphorylation of the protein,
and that the APC/C is not involved in this process.
Background
Terminal differentiation of skeletal muscle is orchestrated
by the family of myogenic regulatory factors (MRFs),
which contains Myf5, MyoD, myogenin and MRF4 (for
review see [1,2]). These factors activate muscle-specific
gene transcription, by binding specific DNA sequences (E-
boxes) as heterodimers with ubiquitous E2A proteins
such as E12 and E47, in cooperation with MEF2 family of
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MADS-box proteins (reviewed in [3]). They have first been
characterized for their ability to convert certain non mus-
cle cells into myoblasts after ectopic expression, a process
known as "myogenic conversion" [4,5]. Among MRFs,
MyoD and Myf5 are usually considered as "determination
factors" since they are required for formation of skeletal
muscle [6], and expressed at the proliferating myoblast
stage, in contrast to myogenin that is induced as cells
undergo cell cycle arrest, and MRF4 that is involved in
myotube maturation [7]. However, recent data have
shown that MRF4 is also expressed at early stages of mus-
cle development, and can act upstream of MyoD and
Myf5 [8].
Interestingly, MyoD bears intimate functional relation-
ships with the cell cycle apparatus (reviewed in [9]): its
transcriptional activity and stability are regulated by cyc-
lin/CDK complexes [10-13], and it can repress cell cycle
activators by physical interaction [14] or by activating
expression of cell cycle inhibitors [15]. Regarding Myf5,
despite numerous observations about the regulation of its
gene and expression pattern during embryonic develop-
ment [7,16], little is understood about its functions, prob-
ably due in large part to its redundancy with MyoD [6].
However, very intriguingly, in cultured myoblasts (C2
cells or primary myoblasts), intracellular protein levels of
Myf5 and MyoD exhibit opposite cell-cycle fluctuations at
the proliferative stage [17], with the result that, during the
early G1 phase of the cell cycle, MyoD levels are high and
Myf5 levels low, whereas the opposite is true at G2. Since
fusion of myoblasts into myotubes occurs during G1
phase, an attractive hypothesis is that the MyoD/Myf5
ratio is an important determinant in myoblasts for the
decision process between proliferation or differentiation.
In this model, MyoD and Myf5 are more than muscle
determination factors, and act in myoblasts as regulators
of the proliferation/differentiation interface. Possibly
connected to this hypothesis, it is interesting to note that,
in cell culture, myoblast differentiation results in two dis-
tinct populations: a majority of plurinucleated myotubes
that contain high levels of MyoD, but no Myf5, and a
minority of quiescent cells, assimilated to "reserve cells",
that contain Myf5 but no MyoD [17,18].
Several studies have demonstrated that the cell cycle vari-
ations of MyoD and Myf5 levels involve their specific and
regulated proteolysis by the proteasome. MyoD degrada-
tion at the end of the G1 phase is promoted by its phos-
phorylation by the CyclinE/CDK2 complex [11,12,19].
Regarding the mechanisms of Myf5 accelerated degrada-
tion at the G2/M transition and throughout mitosis, much
less is known, although it coincides with the phosphoryla-
tion of the protein [20], and seems to depend on the
integrity of a Destruction-box (D-box) domain [21].
To test the hypothesis that the cyclic and alternated degra-
dation of MyoD and Myf5 is not a simple consequence of
proliferation, but an important event in the control of the
proliferation/differentiation interface, we decided to spe-
cifically interfere with the mitotic degradation of Myf5 in
order to gain insights into the biological role of this proc-
ess. To this aim, the purpose of the present work was to
initiate the characterization of the mechanisms regulating
Myf5 mitotic degradation. Since in muscle cells the differ-
entiation process and the cell cycle are tightly connected,
we chose to use non-muscle experimental systems in
which Myf5 mitotic degradation is conserved and can be
studied in a cell cycle-dependent but differentiation-inde-
pendent manner. We show that in Xenopus egg extracts,
which are widely used to study mitosis-specific processes,
Myf5 mitotic degradation occurs through a ubiquitin- and
proteasome-dependent mechanism, in a manner tightly
controlled by its phosphorylation, but independent of
APC/C activity. Myf5 phosphorylation is itself dependent
on the activity of several kinases and phosphatases, and
thus depends on a delicate balance between these activi-
ties that finely tunes Myf5 stability.
Results
Accelerated degradation of Myf5 during mitosis is cell 
cycle- but not muscle-dependent
In order to better define the parameters that control Myf5
cyclic degradation, we first asked whether the responsible
machinery is uniquely dependent on the cell cycle appara-
tus, or whether it requires components restricted to myo-
genic cells. To this end, we derived from HeLa cells a
stable line expressing Myf5 under an inducible promoter.
In this cell line, induced Myf5 is easily detected in non-
synchronized cells, but is absent or very low in cells
arrested in mitosis with nocodazole (figure 1, lanes 1 & 2).
Treatment with the proteasome inhibitor MG132 signifi-
cantly increases Myf5 content in non-synchronized cells
(data not shown), but has a dramatic effect on Myf5
expression in metaphase cells (figure 1, lane 3), suggesting
that Myf5 degradation, which is already rapid in the other
phases of the cell-cycle, is strongly accelerated during
mitosis. In addition, the forms of Myf5 that are stabilized
upon proteasome inhibition in metaphase-arrested cells
are phosphorylated, since treatment of the cell extract
with lambda phosphatase abolishes the shift seen after
electrophoresis without phosphatase treatment (figure 1,
lane 4).
These results strictly reproduce the data obtained with
similar experiments in myogenic cells, showing that Myf5
is strongly destabilized in mitosis, and is stabilized by pro-
teasome inhibitors as a phosphorylated form [20]. Thus,
the machinery responsible for Myf5 mitotic degradation is
present in non-myogenic cells, and does not require mus-BMC Biochemistry 2005, 6:27 http://www.biomedcentral.com/1471-2091/6/27
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cle specific components but only the basal cell cycle
machinery present in all dividing cells.
Myf5 degradation is also cell cycle regulated in Xenopus 
egg extracts
Since Myf5 mitotic degradation is conserved in non-mus-
cle cells, we decided to test whether we could use Xenopus
egg extracts as an in vitro system to dissect the mechanisms
involved. Indeed, Xenopus  egg extracts recapitulate cell
cycle events and have been extensively used for biochem-
ical analyses of mitotic processes, particularly mitosis-spe-
cific protein degradation [22], since it is easy to prepare
large amounts of extracts that reproduce mitotic or inter-
phase conditions [23]. Compared to extracts of synchro-
nized cultured cells, this system presents in addition the
important advantage of limiting dilution of intracellular
components and thus preserving the relative activities of
enzymes such as protein kinases and phosphatases [23].
When radiolabeled in vitro translated Myf5 was incubated
in mitotic extract (CSF, see Methods section), it was read-
ily degraded, in clear contrast with the stability of the
same protein incubated in interphase extract (figures 2A,
2B). As seen in cells, proteasome inhibitors completely
stabilize Myf5 (figure 2D, 2E), which does not occur with
inhibitors of other proteases (data not shown). Thus the
mechanisms governing mitotic-dependent proteasomal
degradation of Myf5 are conserved in Xenopus egg extracts.
It is striking to note that Myf5 appears stable in interphase
Xenopus extracts, although it is highly unstable in non-syn-
chronized (i.e. mostly interphase) cultured cells [21].
Since in cells, the pathway responsible for Myf5 degrada-
tion in interphase is seemingly different from the pathway
operating in mitosis [21], one likely explanation is that
only the mitotic pathway is active in Xenopus extracts. The
fact that cell cycles in early embryos lack G1 phase and
that Xenopus egg extracts do not form nuclei unless sperm
heads are added could explain the absence of this inter-
phase pathway, if it requires intact nuclei for example.
Thus, Xenopus egg extracts appear to be a unique system in
which Myf5 mitotic degradation can be analyzed without
interference of other (i.e. non-mitotic) pathways, and we
decided to pursue our analyses in this system to learn
more about the machinery involved specifically in Myf5
mitotic degradation. We note that the mitotic degradation
pathway of Myf5 appears distinct from that of cyclin B,
which is stable in mitotic extracts (CSF), and degraded
only after calcium activation of these extracts [22].
Myf5 mitotic degradation is controlled by its 
phosphorylation status
When the fate of Myf5 is analyzed by electrophoresis dur-
ing incubation in mitotic extracts (figure 2A), there is,
concomitant with its gradual disappearance, a clear up-
shift in mobility of the protein. By contrast, in interphase
extracts, Myf5 is down-shifted and is stable. This strongly
suggests that, consistent with the results obtained in
mammalian cells, Myf5 mitotic degradation requires its
phosphorylation. In view of the heterogeneity of the
migration of Myf5 in the gel, we tested whether the differ-
ent forms correspond to differentially phosphorylated
molecules of Myf5. We found that indeed, all the slower
migrating forms of Myf5 can be down-shifted to the fast-
est migrating form upon incubation with lambda phos-
phatase (figure 2C, lanes 4 and 6). Thus Myf5 degradation
is strongly correlated with its extensive phosphorylation.
Interestingly, in extracts degrading Myf5, the protein is
gradually shifted to an upper residual form (that we will
call thereafter the hyperphosphorylated form of Myf5, see
discussion for this terminology) that appears to be stable
(figure 2A). By contrast, if Myf5 is dephosphorylated after
translation (using alkaline phosphatase bound to agarose
beads that can be subsequently easily removed from the
reticulocyte lysate), then the protein (deP Myf5) is slower
than untreated Myf5 to reach the hyperphosphorylated
form when incubated in Xenopus egg extracts (compare
figures 2A and 2D) and, as a consequence, can be
degraded to a greater extent (figure 2B). These observa-
tions suggest that Myf5 degradation both requires phos-
phorylation of the protein, and is inhibited by
hyperphosphorylation. To verify this hypothesis, we
tested whether the form accumulating upon prolonged
Myf5 mitotic degradation is conserved in non-muscle cells Figure 1
Myf5 mitotic degradation is conserved in non-muscle 
cells. HeLa-S3 cells expressing Myf5 under an inducible pro-
motor (tetoff) were treated (lanes 2, 3, 4) or not (AS, lane 1) 
with nocodazole (200 ng/ml) for 16 h, as in [20]. In lanes 3 
and 4, cells were treated with a proteasome inhibitor 
(MG132, 50 µM) for 2 h prior to lysis (as described in Meth-
ods). In lane 4, extract was incubated with Lambda phos-
phatase (New England Biolabs) for 30 min at 30°C. 25 µg of 
each extract were resolved by 10% SDS-PAGE and immuno-
blotted with anti-Myf5 antibodies. AS: asynchronous cells; * 
indicates a non specific band recognized by the antibodies 
that can be used as a loading control.
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incubation of Myf5 in mitotic extracts (i.e. the hyperphos-
phorylated form of Myf5) is indeed stable. To this end, we
first incubated Myf5 in mitotic extracts treated with the
phosphatase inhibitor microcystin LR. In these condi-
tions, Myf5 is rapidly accumulated under its hyperphos-
phorylated form (Myf5PPP), and is not degraded (figure
3A). We then incubated this hyperphosphorylated form
of Myf5 in a fresh mitotic extract, in the presence or
Myf5 is degraded in a cell-cycle dependent manner in Xenopus egg extracts, and its degradation is correlated with changes in its  phosphorylation status Figure 2
Myf5 is degraded in a cell-cycle dependent manner in Xenopus egg extracts, and its degradation is correlated 
with changes in its phosphorylation status. (A) Myf5 is phosphorylated and degraded in mitotic (CSF) extracts, but 
dephosphorylated and stable in interphase extracts. Degradation assays were performed as described in Methods; 2 µl samples 
were taken at the indicated times and resolved by 10% SDS-PAGE. (B) Degradation of Myf5 was quantified and normalized 
(start = 100%) : black squares represent the average degradation of Myf5 in interphase extracts (5 independent experiments), 
open circles the average degradation of Myf5 in CSF extracts (7 independent experiments), and black circles the average degra-
dation of dephosphorylated (deP) Myf5 (see Methods section) in CSF extracts (4 independent experiments). Bars represent 
standard deviation. For each lane, a region corresponding to all non-phosphorylated and phosphorylated forms of Myf5 was 
quantified using the ImageQuant software (Molecular Dynamics). The apparent increase of Myf5 level in interphase extracts is 
probably due to the accumulation of all the initially phosphorylated forms of Myf5 (some of them being close to background) 
into the fastest migrating form of Myf5. (C) All the slower migrating forms of Myf5 are phosphorylated: lane 1: in vitro translated 
Myf5; lane 2: in vitro translated Myf5 after 1 h incubation with CSF extract in the presence of 1 µM microcystin LR (this treat-
ment leads to hyperphosphorylation of Myf5 (Myf5PPP), see text and figure 3 for details); lanes 3–6: in vitro translated Myf5 
(lanes 3 and 4), or Myf5PPP (lanes 5 and 6) were immunoprecipitated with anti-Myf5 antibodies and incubated in the absence or 
presence of Lambda phosphatase (λ PPase), as indicated. Samples were resolved by 10% SDS-PAGE and analyzed using a Phos-
phoImager. (D) A mitotic extract was first incubated with 200 µM MG132, or the same volume of pure DMSO as a control, for 
10 min at 25°C; dephosphorylated (deP) Myf5 (see method) was then added to the treated extract. At each time point, 2 µl 
samples were resolved by 10% SDS-PAGE. (E) Relative amounts of Myf5 in the gel shown in D were quantified as above and 
reported on the graph.
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absence of microcystin. As seen in figure 3B, in the pres-
ence of microcystin, the hyperphosphorylated form of
Myf5 remains unchanged and stable. By contrast, in the
absence of microcystin, the hyperphosphorylated form of
Myf5 is dephosphorylated and degraded, in a proteas-
ome-dependent manner (figures 3C &3D).
Altogether, our results strongly support the following
model: degradation of Myf5 is triggered by its phosphor-
ylation, that occurs in multiple sites, but there is a kinetic
competition between phosphorylation and degradation
such that, if Myf5 reaches its hyperphosphorylated form,
it escapes the degradation machinery. In extracts where
both kinases and phosphatases modifying Myf5 are
active, such as Xenopus mitotic egg extracts, the equilib-
rium between both types of activity permits some dephos-
phorylation (and thus subsequent degradation) of Myf5
after it has reached its hyperphosphorylated state, explain-
ing the gradual disappearance of the hyperphosphor-
ylated form seen in figure 2A. By contrast, if phosphatases
are inhibited, then Myf5 remains hyperphosphorylated
and is strongly stabilized (figures 3A, B).
The differences observed in the phosphorylation pattern
of Myf5 between figures 2A and 2D show that, in mitotic
Xenopus  egg extracts, hyperphosphorylation of Myf5 is
accelerated by the intervention of active kinases present in
the reticulocyte lysate in which Myf5 is translated. How-
ever, kinase(s) triggering hyperphosphorylation of Myf5
also exist(s) in mitotic Xenopus egg extracts, since dephos-
phorylated Myf5 rapidly shifts to its hyperphosphorylated
form if the extract is treated with the phosphatase inhibi-
tor microcystin (data not shown). This indicates that the
stability of Myf5 is tightly dependent upon the kinase/
phosphatase equilibrium of the extracts, and suggests that
in cells, multiple mechanisms – including perhaps hyper-
phosphorylation – may be used to control Myf5 stability
under different biological conditions.
Several signaling pathways are likely to be involved in the 
control of Myf5 stability
An important question is the nature of the kinase(s)
responsible for Myf5 mitotic degradation. An evident can-
didate is the CDK1 kinase, which is the hallmark of
mitotic status, since its activity is high during mitosis but
abruptly decreases upon mitosis exit, due to the degrada-
tion of its activator cyclin B [24,25]. Indeed, in vitro trans-
lated Myf5 can be directly phosphorylated by CDK1/
cyclin B, as seen by the shift of the protein after its incuba-
tion with the purified kinase (figure 4A, lanes 1&3). How-
ever, if the kinase CDK1 is reactivated in interphase egg
extracts by addition of non-degradable cyclin B [26],
although phosphorylation of Myf5 resumes in a pattern
very similar to that seen in CSF extracts, in most experi-
ments Myf5 is not significantly degraded (data not
shown). This suggests that at least one other kinase is
required for Myf5 degradation, in addition to CDK1. We
observed that Myf5 can nevertheless be degraded in some
mitotic extracts resulting from reactivation of CDK1 in
interphase extracts (data not shown), pointing to the pos-
sible involvement of the MAP kinase family. Indeed, the
activity of MAP kinases can vary in interphase Xenopus egg
extracts, depending on the protocols used to prepare
them, which may or may not entail the degradation and/
or inactivation of the upstream MAPKKK c-Mos [27]. We
found that the protein kinase Erk (MAPK) is also able to
phosphorylate Myf5 in vitro, apparently at different sites
from CDK1/cyclin B (figure 4A, lanes 4&5). These results
suggest that these two kinases may cooperate in the regu-
lation of Myf5 stability. However, other enzymes may also
be involved. For example, we found that Ca2+ – at very low
concentrations – is important for Myf5 degradation, sug-
gesting that a calcium-dependent kinase or phosphatase
could be involved in the regulation of Myf5 stability.
Indeed, as shown in figure 4B, degradation of Myf5 is
accelerated in mitotic extracts (that are prepared in the
presence of EGTA) supplemented by a low concentration
of Ca2+, as compared to degradation in the same extract
without supplementation. This reproducible result shows
that the concentration of free Ca2+ that exists in the pres-
ence of the strong calcium chelator EGTA, albeit extremely
low (in the range of 10-7M [28]), is nevertheless signifi-
cant enough to alter the rate of degradation of Myf5. Inter-
Hyperphosphorylated Myf5 is stable Figure 3
Hyperphosphorylated Myf5 is stable. An equal volume 
of reticulocyte lysate containing in vitro translated Myf5 and 
of Xenopus mitotic egg extract (CSF) were incubated 
together for 60 min in the presence of 1 µM microcystin LR. 
At each time point, 0.5 µl samples were analyzed by 10% 
SDS-PAGE (panel A). After this initial incubation, 2 µl of the 
reaction mixture containing hyperphosphorylated Myf5 
(Myf5PPP) were further incubated in 18 µl of fresh mitotic 
extract, either in the presence of 1 µM microcystin (panel B) 
or without inhibitor addition (panel C), or without microcys-
tin and in the presence of the proteasome inhibitor MG132 
(200 µM, panel D). At each time point, 2 µl samples were 
analyzed by 10% SDS-PAGE.
A
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estingly, the activity of the calcineurin phosphatase has
been shown to be sensitive to such low concentrations of
Ca2+ [29]. This range of calcium concentrations does not
trigger cyclin B degradation, which requires a transient
increase of the concentration of free calcium from 10-7 to
10-5 M for its activation [28].
To define which kinases are required for Myf5 mitotic deg-
radation, we tested a panel of specific inhibitors (see Table
1) targeting the MAP kinase family, the GSK3 kinase, PKC,
CDK1/cyclin B, and the calcineurin phosphatase. Unfor-
tunately, we were unable to reproducibly alter Myf5 deg-
radation using these inhibitors, although most of them
altered Myf5 phosphorylation status (see Table 1). Over-
all, the many attempts that we have made to clarify the
question of the kinases involved in Myf5 degradation in
Xenopus extracts have led us to the conclusion that Myf5
degradation probably involves several kinases, but is so
sensitive to the kinase/phosphatase equilibrium that
alteration of the activity of many signaling pathways
induces complex and contradictory effects on Myf5 stabil-
ity that cannot be clarified by simple pharmacological
approaches.
In addition, it seems likely that although multiple phos-
phorylations of Myf5 are required for its degradation,
none of the individual phosphorylation sites is absolutely
necessary. We investigated this question by mutational
analyses of Myf5 in order to identify phosphorylation
sites important for its degradation. Since Myf5 possesses
about 20% serine/threonine (S/T) residues and many
potential phosphorylation sites in its primary sequence,
making it difficult to systematically change them all into
non-phosphorylable residues, we decided to concentrate
our work on S/T-proline (S/TP) motifs, which are poten-
tial phosphorylation sites for both CDK1/cyclin B and
MAPK family kinases. We mutated into alanines the five
serines (S10, S23, S158, S172, S231), and the threonine (T242)
that are present in Myf5 S/TP motifs, and analyzed the
degradation of these mutants in mitotic egg extracts.
Although most mutants showed an altered pattern of
phosphorylation when compared to the wild type pro-
tein, indicating that the mutated residues are likely to be
phosphorylated in extracts, none of them was clearly sta-
bilized (not shown). The fact that the mutant S158A,
which was found to be stabilized in interphase but not
mitotic mammalian cells [21], is still efficiently degraded
in mitotic egg extracts, underlines that only the mitotic
degradation of Myf5 is active in these extracts. If it cannot
be excluded at present that other phosphorylation sites
are the key determinants of Myf5 stability, there is another
possible interpretation, that we presently favor in view of
the probable involvement of both (at least) CDK1/cyclin
B and MAP kinases into Myf5 degradation. That is, in a
process analogous to that reported for the CDK inhibitor
Sic1 in budding yeast [30,31], it would be the number of
phosphorylated residues rather than their identity that
controls Myf5 stability. If this hypothesis holds true, then
only the mutation of most of these sites would signifi-
cantly alter the degradation of the protein.
Myf5 degradation requires its prior ubiquitylation
Regulated protein degradation by the proteasome most
often requires the prior conjugation on the substrate of a
poly-ubiquitin chain that acts as a signal targeting the sub-
strate to the proteasome [32]. Incubation of Myf5 in Xeno-
pus mitotic egg extracts in the presence of proteasome and
de-ubiquitylating enzymes inhibitors indeed led to the
rapid formation of ubiquitylated forms of Myf5 (figure
5A). To test whether these ubiquitylated forms are obliga-
tory intermediate products in Myf5 degradation, we
titrated wild type ubiquitin (Ub) with a mutant form of
Ub in which all the lysines have been replaced by
Several signaling pathways are likely to control Myf5 mitotic  degradation Figure 4
Several signaling pathways are likely to control Myf5 
mitotic degradation (A) 1 µl of untreated (upper panel) or 
dephosphorylated (deP, lower panel) Myf5 was incubated 
with buffer (lane 2), recombinant CDK1/cyclin B (New Eng-
land Biolabs, 40U, lane 3), recombinant Erk2 (New England 
Biolabs, 200U, lane 4) or both kinases (lane 5) for 30 min at 
30°C. The reaction mix was resolved by 10% SDS-PAGE. 
"Start" is a non-incubated control. (B) Myf5 degradation is 
sensitive to very low concentrations of calcium: a mitotic 
extract was prepared using XB without CaCl2 but supple-
mented with 6 mM EGTA (see Methods), then incubated 
with 0.1 mM CaCl2 and 6 mM EGTA, or an equivalent vol-
ume of water as a control, for 10 min at 25°C. 2 µl of Myf5 
were incubated for 1 hour with 18 µl of treated extract. 2 µl 
samples were resolved by 10% SDS-PAGE at the beginning 
and the end of the reaction. Myf5 degradation rate was quan-
tified as previously described; the graph represents mean val-
ues of 3 experiments. Bars represent standard deviations.
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arginines (UbK0). Since this lysine-less mutant cannot be
itself conjugated by Ub, it acts as a chain terminator if
integrated in a Ub-chain [33]. When added to a mitotic
extract, this mutant strongly inhibits both Myf5 ubiquit-
ylation (figure 5B) and degradation (figure 5C) in a con-
centration-dependent manner. Thus efficient poly-
ubiquitylation of Myf5 is required for its subsequent deg-
radation, showing that Myf5 is degraded in a ubiquitin-
and proteasome- dependent process.
The E3 responsible for Myf5 ubiquitylation is not the APC/
C
Protein ubiquitylation requires an enzymatic cascade
involving 3 types of proteins called E1 (Ub-activating pro-
tein), E2 (Ub-carrier protein) and E3 [34]. In this cascade,
the E3 component recruits both an E2 and the substrate to
favor ubiquitylation of the latter, and thus acts as the spe-
cificity factor for the reaction. As a consequence, eukaryo-
tic cells contain a very high number of E3 proteins [35].
However, many substrates degraded by the ubiquitin-pro-
teasome pathway in mitosis (among which the mitotic
cyclins and securin) are targeted for ubiquitylation by the
E3 ligase APC/C (Anaphase-Promoting Complex / Cyclos-
ome) [36,37]. Ubiquitylation of some of these proteins
depends on a loosely conserved Destruction-box (D-box)
motif, which is thought to be recognized by the APC/C
adaptor proteins Cdc20/Fizzy [25,38] and Cdh1 [39]. A
D-box-like motif is present in Myf5 sequence, and substi-
tution of residues into this 9-amino-acid sequence signif-
icantly stabilizes the protein during mitosis [21],
suggesting that Myf5 could be an APC/C substrate. How-
ever, the degradation pathway of Myf5 in mitotic cells
appears different with respect of both timing and mecha-
nism from that of known substrates of the APC/C [21]. To
elucidate this apparent dilemma, we decided to test in our
system whether the APC/C is responsible for Myf5 ubiq-
uitylation.
We first used Xenopus interphase extracts in which APC/C
is specifically activated by translation in the extract of the
APC/C regulator Cdh1 (Fizzy-related in Xenopus), as these
extracts have been shown to be able to efficiently degrade
most known APC/C substrates in a Cdh1-dependent man-
ner [39]. As shown in figure 6A, Myf5 is rapidly dephos-
phorylated and is stable for 1 h in these extracts, although
the APC/C substrate Xkid [40], used here as a control, is
completely degraded after 30 minutes, as expected. This
result strongly suggests that APC/C is not involved in
Myf5 degradation. However, Myf5 could be an unusual
APC/C substrate requiring to be phosphorylated to be rec-
ognized by this E3. If so, then its dephosphorylation in
these extracts could explain its stability. To avoid dephos-
phorylation, we decided to test by immunodepletion
approaches whether the presence of APC/C is required for
Myf5 ubiquitylation in mitotic eggs extracts. In these
extracts, APC/C is active against certain substrates such as
cyclin A [41], but its activity towards other substrates such
as cyclin B is inhibited by the cytostatic factor (CSF). In
order to abolish CSF effect and study a fully active APC/C,
we treated a CSF extract with 1 µM microcystin LR [42].
Since in these conditions, as described above, Myf5 degra-
dation is inhibited due to the accumulation of the protein
in its hyperphosphorylated form, we fractionated the acti-
vated extract on a DEAE column. Both APC/C and E3 act-
ing on Myf5 were eluted with 0.25 M NaCl (figure 6B,
lanes 2). Immunodepletion of APC/C, using antibodies
directed against its constitutive subunit CDC27, fails to
abolish Myf5 ubiquitylation in the 0.25 M NaCl fraction,
whereas, in the same conditions, cyclin B is no longer
ubiquitylated (figure 6B, lanes 5). Moreover, cyclin B, but
not Myf5, is ubiquitylated in the presence of the proteins
immunoprecipitated with anti-CDC27 antibodies (figure
6B, lanes 4). Altogether, these results show that, at least in
Xenopus egg extracts, the E3 responsible for Myf5 ubiquit-
ylation in mitosis is not the APC/C, but another E3 that
remains to be identified.
Table 1: List of kinase and phosphatase inhibitors tested in Xenopus egg extracts for their potential effect on Myf5 degradation These 
inhibitors were purchased from Sigma-Aldrich, stock solutions were prepared in ethanol or DMSO, following the furnisher 
instructions.
Inhibitor Action Concentrations tested Effect on Myf5 
phosphorylation status (*)
References
Indirubin-3'-oxime GSK3β and CDK5 inhibitor 101 to 100 µM Partial inhibition [54, 55]
Roscovitine CDK/cyclin inhibitor 100 µM2 Partial inhibition [56–58]
Staurosporine Broad spectrum kinase inhibitor (among 
which: PKA, PKG, CaMK, MLCK, PKC)
11 to 10 µM Strong inhibition [59, 60]
U0126 MEK1/2 inhibitor 501 to 100 µM Partial inhibition [61, 62]
GF109203X PKC inhibitor 51 to 50 µM Partial inhibition [63, 64]
Cyclosporin A Calcineurin inhibitor 11 to 10 µg/ml No effect [65, 66]
Microcystin LR Broad spectrum phosphatase inhibitor 1 µM Hyperphosphorylation [42, 67]
1 Usual concentration for treatment of cell cultures
2 Efficiency of this concentration was tested by measuring H1 Kinase activity after treatment.
(*) as judged by electrophoretic migration patternBMC Biochemistry 2005, 6:27 http://www.biomedcentral.com/1471-2091/6/27
Page 8 of 15
(page number not for citation purposes)
The E3 involved in Myf5 ubiquitylation preferentially 
recognizes phosphorylated forms of Myf5
To further characterize the E3 responsible for Myf5 ubiq-
uitylation, we undertook fractionation of mitotic egg
extracts by chromatography (figure 7A). In this type of
experiments, the fractions containing the E3 activity of
interest are identified by their ability to allow ubiquityla-
tion of Myf5 when added to a reaction mixture containing
purified E1, E2, Ub and radiolabeled Myf5. The E3 activity
was retained on a DEAE column, as described above (fig-
ure 6B, lane 2), and quantitatively recovered within the
proteins eluted from the column with 0.25 M NaCl. Fur-
ther fractionation of the DEAE 0.25 M NaCl eluate on a
UnoQ column reproducibly led to the ubiquitylation pat-
tern shown in figure 7B: a weak ubiquitylation activity
could be detected in several fractions, but the major activ-
ity resulted from proteins eluted in fraction 15 (about 0.3
M NaCl). We failed to observe a robust ubiquitylation at
this stage, probably because we removed from the active
fractions the kinases important for Myf5 ubiquitylation,
but also because the E3 appeared to be very unstable.
Indeed its activity was essentially lost a few hours after
UnoQ purification (data not shown). However, we used
freshly prepared E3 fractions to test whether this E3 dis-
criminates between phosphorylated and non-phosphor-
ylated forms of Myf5, as suggested by our previous
analyses in crude extracts. We took advantage of the fact
that Myf5 is already phosphorylated during its translation
in reticulocyte lysate and tested the fraction from the
UnoQ column containing the E3 activity, for its ability to
mediate ubiquitylation of either untreated (phosphor-
ylated) Myf5 or Myf5 dephosphorylated (deP Myf5) by
treatment of the lysate with alkaline phosphatase. Figure
7C shows that ubiquitylation of Myf5 occurs when using
the phosphorylated form of Myf5, but is strongly dimin-
ished (although not abolished) when using non-phos-
phorylated Myf5. This result confirms that
phosphorylation of Myf5 favors its recognition by the E3
mediating its ubiquitylation.
Discussion
The striking differential cell cycle-regulated degradation of
both MyoD and Myf5 in proliferating myoblasts suggests
that these two proteins, albeit homologous and partially
redundant, carry out specific functions that must be
turned down at a specific cell cycle stage. Physical and
functional interactions of MyoD with cell cycle regulators,
that impinge on the proliferation/differentiation interface
in myoblasts, show that certain of these functions are
interfering with cell cycle progression and suggest that, at
least for MyoD, its cyclic degradation is required for main-
tenance of the proliferative status of the cells. For Myf5,
much less is known, but it is likely that the same rationale
can be followed, i.e. that its accelerated degradation at the
Polyubiquitylation of Myf5 is required for its degradation Figure 5
Polyubiquitylation of Myf5 is required for its degrada-
tion. (A) Myf5 is polyubiquitylated in mitotic extracts: Myf5 
was incubated in a mitotic extract in the presence of ubiqui-
tin (1 mg/ml), MG132 (200 µM) and ubiquitin aldehyde (5 
µM). At the times indicated, 2 µl samples were analyzed by 
10% SDS-PAGE to visualize the formation of high-MW 
adducts ((Ub)n-Myf5, poly-ubiquitylated Myf5 molecules). (B) 
Lysine-less (K0) ubiquitin inhibits Myf5 polyubiquitylation: 
Myf5 ubiquitylation was performed in a mitotic extract in the 
presence of MG132 (200 µM), ubiquitin aldehyde (1 µM), 
ubiquitin (Ub) and lysine-less-ubiquitin (UbK0) at the indi-
cated concentrations, for 30 min at 25°C. (C) Lysine-less 
ubiquitin stabilizes Myf5: Degradation assays were performed 
in 20 µl reaction mixtures containing 16 µl of mitotic extract, 
2 µl of radiolabeled in vitro translated Myf5 and a mixture of 
wild type and K0 ubiquitin as indicated. The reaction was 
performed at 25°C for 40 min, 2 µl samples were resolved 
by 10% SDS-PAGE. "START" corresponds to a 2 µl sample 
taken at time 0 from the reaction containing 1 mg/ml Ub. 
Radioactivity was quantified as previously described (see leg-
end of figure 2) and percentages of degradation were calcu-
lated for each Ub/UbK0 ratio from the difference between 
the times 0 (not shown) and 40 minutes.
0 15 30 60 min
(Ub)n-M y f 5
Myf5
A
B
C
Ub
UbK0
0
1
49.1
0.25
0.75
37.5
0.5
0.5
32.2
0.75
0.25
9.3
1
0
5.8
UbK0 (mg/ml):
Ub (mg/ml):
% degradation
S
T
A
R
T
-
U
bBMC Biochemistry 2005, 6:27 http://www.biomedcentral.com/1471-2091/6/27
Page 9 of 15
(page number not for citation purposes)
late G2/M phase of the cell cycle is required for progres-
sion through subsequent phases.
Nature of the E3 responsible for Myf5 mitotic 
ubiquitylation
A strong argument in favor of an involvement of APC/C in
Myf5 mitotic degradation was that Myf5 contains in its
sequence a putative D-box motif, the mutation of which
partially stabilizes Myf5 in mitotic cells, but not in inter-
phase cells [21]. However, this degradation did not
depend on UbcH10, the E2 known to function with APC/
C, and the timing of degradation of Myf5 appeared differ-
ent from that of known substrates of the APC/C: when
examined in individual cells, Myf5 was always degraded
before cyclin B, but the timing of its degradation relative
to that of cyclin A appeared highly variable [21]. In addi-
tion, it is noteworthy that ubiquitylation of known sub-
strates of the APC/C is not regulated by phosphorylation
of the substrate [43]; the fine temporal tuning of ubiquit-
ylation is rather controlled by post-translational modifi-
cations of the APC/C itself, respectively the core complex
[44] or its activators [45], which modulate the activity of
the E3. Altogether, the involvement of APC/C in Myf5
mitotic degradation remained an open issue.
Since mitotic degradation events are usually conserved
between cells and organisms, the Xenopus egg extract sys-
tem has been widely used to dissect these events and par-
ticularly to study the functions of APC/C [36,46,47]. To
resolve the dilemma relative to the possible involvement
of APC/C in the mitotic degradation of Myf5, we tested
whether this complex is important for Myf5 mitotic deg-
radation in Xenopus extracts. We found by two different
approaches that APC/C does not participate to the ubiq-
uitylation of Myf5 in Xenopus  egg extracts. This result
raises two questions. The first is whether the Xenopus sys-
tem is representative of other cells and particularly myob-
lasts as far as Myf5 mitotic degradation is concerned. At
this point, we believe that there is no reason to doubt it,
as it would be a surprise if Myf5 was degraded in this sys-
tem in a mitotic-dependent but different manner to that
in cultured cells. Since the mechanisms controlling mito-
sis are conserved in higher eukaryotes, the frog system has
been central for the understanding of many mechanisms
controlling mitosis (including the discovery of APC/C)
and, up until now, most data obtained with Xenopus egg
extracts for APC/C substrates have been confirmed in
other systems. But obviously a definitive conclusion on
the role of APC/C in Myf5 degradation will require further
studies in myoblasts. The second question is why, if APC/
C is not important for Myf5 mitotic degradation, the
Destruction-box mutants of Myf5 were specifically stabi-
lized in cells during mitosis [21]. We are presently not
able to answer this question, but several observations on
this issue may be important. First, the D-box is a loosely
The E3 responsible for Myf5 ubiquitylation is not the APC/C Figure 6
The E3 responsible for Myf5 ubiquitylation is not the 
APC/C. (A) In vitro translated Xkid (upper panel) or Myf5 
(lower panel) were incubated in 15 µl Xenopus interphase 
egg extract in which Cdh1 has been translated [39]. After the 
times indicated, 2.5 µl were analyzed by SDS-PAGE and 
fluorography. (B) 1 ml of mitotic extract was activated with 1 
µM microcystin LR (in order to fully activate APC/C), then 
fractionated on a DEAE column (see Methods). Bound pro-
teins were eluted in two steps with buffer A containing 0.25 
M and 0.5 M NaCl, respectively. Each fraction (lanes 2 & 3) 
was compared to a control reaction containing buffer (lane 
1) for its ability to mediate ubiquitylation of either cyclin B 
(upper panel) or Myf5 (lower panel). Lanes 4–7: the 0.25 M 
NaCl eluate that mediates both cyclin B and Myf5 ubiquityla-
tion was then subjected to immunoprecipitations using either 
anti-Cdc27 or control antibodies. For each immunoprecipita-
tion, both the material bound to the beads or the superna-
tant were analyzed for ubiquitylation activity using cyclin B 
(upper panel) or Myf5 (lower panel) as a substrate. (Ub)n-
cycB and (Ub)n-Myf5 indicate poly-ubiquitylated forms of cyc-
lin B and Myf5, respectively.
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conserved motif that can be found in many proteins, and
several examples show that it cannot be automatically
assimilated to a signature for targeting to the APC/C (see
for example [40]). Thus, Myf5 D-box could be important
for Myf5 mitotic degradation without actually acting as a
genuine D-box motif. Second, there are several degrada-
tion pathways acting on Myf5 in cells, and one cannot
exclude that the Destruction-box mutants of Myf5 inter-
fere with other systems than the strictly mitotic pathway.
In support of this notion, it is important to note that these
mutants are only partially stabilized in mitotic cells: their
further stabilization by proteasome inhibitors indeed
indicates that proteasomes are still actively degrading
these mutants in mitotic cells [21]. Moreover, we found
no stabilization of these mutants in Xenopus egg extracts
(data not shown), which, as shown by the absence of deg-
radation of Myf5 in interphase, seem to possess only the
mitotic pathway acting on Myf5. Third, because the D-box
motif of Myf5 is adjacent to the DNA binding domain,
these mutants have a decreased affinity for DNA as com-
pared to the wild type protein [48]. Since binding to DNA
and presence of various partners have been shown to alter
MyoD degradation [49,50], it is possible that conforma-
tional changes induced by mutations in the D-box motif
of Myf5 impact on its mitotic degradation by indirect
ways.
Myf5 ubiquitylation is controlled by phosphorylation Figure 7
Myf5 ubiquitylation is controlled by phosphorylation. (A) Scheme of Myf5 E3 purification : for details see Methods sec-
tion. (B) 2 ml of mitotic extract were fractionated as described in A; the fractions obtained from the UnoQ column were 
screened for their ability to ubiquitylate radiolabeled Myf5 in the presence of a ubiquitylation mix containing GST-Ub (see 
Methods). The reactions were resolved by 10% SDS-PAGE. (Ub)n-Myf5 indicates poly-ubiquitylated forms of Myf5. (C) The 
fraction containing the E3 was concentrated about 10-fold using a Centricon 10 K (Millipore). Untreated Myf5 (lanes 1 to 3) or 
dephosphorylated (deP) Myf5 (lanes 4 to 6) was incubated with the ubiquitylation mix alone (lanes 2, 5) or together with 6 µl 
of concentrated fraction containing the E3 (lanes 3, 6) for 30 minutes at 25°C. Non incubated Myf5 was loaded in lanes 1 and 4 
(START) as control. Similar amounts of radioactive Myf5 and dephosphorylated Myf5 were used.
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Altogether, we believe that our data in Xenopus are a solid,
albeit non definitive, argument in favor of the non-
involvement of APC/C in Myf5 mitotic degradation. Inter-
estingly, there are up to now few substrates known to be
degraded in mitosis by the ubiquitin proteasome path-
way, and whose ubiquitylation is not due to the APC/C
[51]. The high incidence of the phosphorylation status of
Myf5 on its ubiquitylation and degradation suggests that
an E3 from the SCF family of complexes could be involved
[43,52]. Since few tools are available to study SCF com-
plexes in Xenopus egg extracts, we are currently analyzing
the potential involvement of these complexes in Myf5
ubiquitylation using mammalian systems.
Control of Myf5 degradation by phosphorylation
Based on the homology of Myf5 to MyoD, we expected a
simple mechanism in which a unique phosphorylation
would trigger Myf5 mitotic degradation. Indeed phospho-
rylation of MyoD on its serine 200 by the CDK2/cyclin E
kinase has been shown to be critical to entail rapid degra-
dation of this protein at the end of the G1 phase of the
cell-cycle [12]. However, although this simple scenario
cannot be excluded at the moment, our results on the
mechanisms controlling Myf5 stability are drawing a
much more complex picture.
We found a significant degree of variability from extract to
extract in the phosphorylation status of Myf5, that pre-
vented us from obtaining clear conclusions on the nature
of the kinase(s) controlling Myf5 ubiquitylation and deg-
radation. We believe that some of the problems were due
to the origin of the substrate we used. Indeed, there is a
clear interference in this assay of kinases present in the
reticulocyte lysate in which Myf5 was translated, and we
observed a variability between different lysates that was
likely to contribute to the difficulty of obtaining solid con-
clusions. However, attempts to translate Myf5 in other
systems derived from wheat-germ or E. coli, or to co-trans-
late the Myf5 partner E12 did not fundamentally solve the
problem of variability.
We thus think that the problem resides elsewhere, in the
complexity of Myf5 phosphorylation that makes the deg-
radation of this protein extremely sensitive to the kinase/
phosphatase equilibrium of the extracts. The concordant
picture arising from all our attempts to modify Myf5 sta-
bility in Xenopus  egg extracts, either by inhibition of
kinases or phosphatases or by single mutations of the S/
TP sites of Myf5, is that several enzymes impinge on Myf5
phosphorylation status and thus Myf5 stability, and that
Myf5 ubiquitylation apparently requires phosphorylation
on multiple sites. However, although most S/TP sites of
Myf5 seem phosphorylated in mitotic extracts, as their
mutation affects Myf5 migration in gel, none of these sites
seems to be absolutely necessary for efficient degradation
of the protein. This could suggest that it is phosphoryla-
tion itself or, by analogy with data obtained for the CDK
inhibitor Sic1 [30,31], the number of phosphorylated res-
idues rather than their identity that is the important
parameter for Myf5 ubiquitylation.
An unexpected result in our experiments was the observa-
tion that a phosphorylated form of Myf5 was completely
resistant to degradation. Because this form was the latest
phospshorylated form to appear and the slowest migrat-
ing in gel, we called it the hyperphosphorylated form of
Myf5. This terminology is coherent with the observation
that Myf5 apparently escapes degradation only when it is
fully phosphorylated. However at this point we cannot
exclude that a single phosphorylation event is responsible
for both Myf5 stabilization and shift to the slowest
migrating form. An important question is whether the sta-
bilizing hyperphosphorylation of Myf5 exists in cells and
particularly in myoblasts. A possibility is that this hyper-
phosphorylation is not a standard process seen at each cell
cycle, but a regulated mechanism occurring only in certain
physiological situations. Alternatively, as it has been sug-
gested recently for MyoD [13], such a mechanism could
allow a low amount of Myf5 to be preserved during pas-
sage through mitosis, in order for the cell to be able to
mobilize it immediately after completion of cell division.
Conclusion
In this article, we describe the work we performed using
the Xenopus egg extract system to better define the mecha-
nisms that control Myf5 degradation in mitosis. Alto-
gether, our data are in favor of the following model (figure
8): in mitotic extracts, Myf5 is phosphorylated on numer-
ous residues. Some of these residues, once phosphor-
ylated, are recognized by an E3, distinct from APC/C, that
mediates Myf5 polyubiquitylation, targeting it to the pro-
teasome for degradation. However, when Myf5 is fully
phosphorylated, it somehow escapes degradation and is
stabilized. In such a model, phosphorylation of Myf5 is
necessary for its mitotic ubiquitylation, but can also be
used to stabilize the protein. Thus the stability of the pro-
tein can be finely tuned by differential activation of vari-
ous signaling pathways, providing a precise and rapid way
to adapt Myf5 levels in cells in function of the cell cycle
stage.
Methods
Cell culture and lysates
HeLa-S3 cells expressing mouse Myf5 (UN6 clone) under
an inducible promoter (tet-off) are usually cultured in
DMEM containing 10% FCS (Cambrex), 1000 U/ml pen-
icillin/streptomycin, 2 mM L-Glutamine, 500 µg/ml
G418, 170 U/ml hygromycin B and 1 µg/ml tetracycline.
Expression of Myf5 is induced for 24 hours by washing the
cells three times with PBS and adding fresh medium with-BMC Biochemistry 2005, 6:27 http://www.biomedcentral.com/1471-2091/6/27
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out tetracycline. To prepare lysates, cells are scraped in
cold PBS and centrifuged for 10 min at 1000 rpm. The pel-
let is then resuspended in about 5 pellet volumes of 20
mM Tris pH 7.5, 137 mM NaCl, 10% glycerol, 1% NP40,
1 mM orthovanadate, 20 mM NaF, protease inhibitor mix
(Complete, Roche-Boehringer), and incubated for 30 min
on ice, while vortexing every 5 min. The lysate is then cen-
trifuged for 8 min at 16000 × g. The supernatant is
removed and protein concentration is measured using
BSA as a standard (Bradford Reagent Assay, Pierce).
Xenopus egg extracts
Mitotic extracts are prepared by gently crushing oocytes
arrested in metaphase of meiosis II, with CDK1/cyclin B
kinase activity maintained at a high level by cytostatic fac-
tor (CSF); these extracts, called CSF extracts, thus repro-
duce a pseudo-mitotic state. When eggs are fertilized,
penetration of sperms induces a calcium wave that inacti-
vates CSF activity and triggers cyclin B degradation, and
CDK1 activity rapidly declines to an interphase level
(reviewed in [53]). A synchronous release from CSF arrest
can be artificially induced by activating the eggs with cal-
cium ionophore treatment. To prepare extracts, eggs are
dejellied in a solution containing 2% L-Cystein (pH 7.5),
then washed extensively in XB Buffer (100 mM KCl, 0.1
mM CaCl2, 1 mM MgCl2, 10 mM HEPES pH 7.7, 50 mM
Sucrose) supplemented with 6 mM EGTA and lysed by
centrifugation for 20 min at 16000 × g. The supernatant
(except the floating lipidic phase) is removed and supple-
mented with an ATP regenerating system (1.25 mM ATP,
1.25 mM MgCl2, 1.9 mM Creatine Phosphate, 6.25 µg/ml
Creatine Phosphokinase), leupeptin (25 µg/ml) and cyto-
chalasin B (25 µg/ml). After centrifugation for 20 min at
16000 × g, the supernatant is removed, aliquoted and fro-
zen in liquid nitrogen. Frozen aliquots are kept at -80°C
for several weeks. For interphase extracts, eggs were dejel-
A model for Myf5 mitotic degradation pathway Figure 8
A model for Myf5 mitotic degradation pathway. Myf5 is subjected to multiple phosphorylations in Xenopus mitotic egg 
extracts, that tightly control its stability: phosphorylation of the protein leads to its ubiquitylation by an E3 distinct from APC/
C, and its subsequent degradation by the proteasome. However, a hyperphosphorylated form of Myf5 remains stable (see text 
for details).
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lied as described above, then activated by calcium iono-
phore and incubated for 10 minutes in XB containing 10
µg/ml cycloheximide (SIGMA-ALDRICH). Eggs were then
lysed as described above.
In vitro production of [35S] methionine-labeled proteins
Human cyclin B, mouse Myf5 and frog Xkid purified plas-
mids are transcribed and translated in vitro in the presence
of L-[35S]-methionine (Amersham, Redivue mix) in rabbit
reticulocyte lysates, following manufacturer's instructions
(Promega TNT Quick coupled system), then loaded on
pre-equilibrated (Tris-HCl 20 mM, pH7.5) Biospin6 col-
umns (BioRad), in order to eliminate non-incorporated
radioactive methionine. The dephosphorylated form of
Myf5 is obtained by incubating freshly translated Myf5
with alkaline phosphatase linked to agarose beads
(SIGMA-ALDRICH) for 30 min at 37°C. The mix is then
loaded on BioSpin6 columns as above to remove both the
beads and the excess radioactive methionine.
In vitro degradation and ubiquitylation assays
For degradation assays, 18 µl of mitotic or interphase
extracts are usually mixed with 2 µl of reticulocyte lysate
containing the radioactive (in vitro translated) substrate
and are further incubated at 25°C. At appropriate time
points, 2 µl samples are subjected to SDS-PAGE (10%
gels) analysis. Gels are then dried, exposed and the radio-
active bands are quantified using a PhosphoImager
(Molecular Dynamics). Ubiquitylation assays are per-
formed in the presence of 200 µM MG132 (BioMol), 5 µM
Ubiquitin aldehyde (BioMol), 1 mg/ml Ubiquitin
(SIGMA-ALDRICH), 5 mM MgCl2  and 1 mM ATPγS.
Lysineless mutant ubiquitin (UbK0) is purchased to Bos-
ton Biochem.
Purification of Myf5 E3
A mitotic extract is diluted twice in buffer A (20 mM Tris
pH7.5, 1 mM DTT) supplemented with 1% Igepal CA-630
(Sigma), then incubated for 15 min at 4°C with the same
volume of AffigelBlue DEAE beads (BioRad) pre-equili-
brated in buffer A + 0.5% Igepal. The beads are then exten-
sively washed with a large excess of buffer A containing
0.5% Igepal, then with buffer A only. Myf5 E3 activity is
eluted with buffer A containing 0.25 M NaCl. This fraction
is directly loaded on a UnoQ1 or a UnoQ12 column (Bio-
Rad) pre-equilibrated with buffer A containing 0.2 M
NaCl. A gradient from 0.2 M to 0.5 M of NaCl is applied
to the column, and Myf5 E3 activity is eluted at a concen-
tration of approximately 0.3 M NaCl. The fractions
obtained from the different columns are screened for their
ability to ubiquitylate radiolabeled Myf5 in the presence
of the ubiquitylation enzymes E1 (Xenopus, 50 ng), E2
(recombinant UBCH5B, 0.5 µg), purified recombinant
GST-Ub (1 mg/ml) or ubiquitin (1 mg/ml), 1 mM ATP, 5
mM MgCl2, 5 µM ubiquitin aldehyde, 200 µM MG132, 20
mM Tris pH7.5. Ubiquitylation reactions are performed
with 1 µl of radiolabeled Myf5, 6 µl of each fraction, in a
final volume of 10 µl, and incubated for 30 min at 25°C.
After appropriate incubation time, the reaction is stopped
by addition of sample buffer, and the samples are ana-
lyzed by electrophoresis and PhosphoImaging.
Antibodies
Anti-Myf5 (C-20, Santa Cruz) is diluted 1:1000 for West-
ern Blotting. Secondary anti-rabbit-HRP (Amersham) is
diluted 1:10000. APC/C immuno-precipitations are real-
ized with a home-made affinity-purified anti-Cdc27 [46].
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